SAN DIEGO, CA--(Marketwire - August 09, 2010) - Lpath, Inc. (OTCBB: LPTN), the category leader of lipidomics-based therapeutics, has been invited to present at the 2010 Southern California Investor Conference to be held at The Island Hotel in Newport Beach on August 17, 2010.
The president and CEO of Lpath, Scott R. Pancoast, is scheduled to present at 9:00 a.m. Pacific time, with one-on-one meetings to be held on the same day. A simultaneous webcast will be available at http://events.powerstream.net/002/00271/20100817_SCIC_T4/
The Southern California Investor Conference is open to the public and will feature presentations from the senior management of leading Southern California companies. For registration and information, go to www.CaliforniaStocks.com or call 866-928-2600.
About Lpath
San Diego-based Lpath, a therapeutic antibody company, is the category leader in lipidomics-based therapeutics, an emerging field of medicine that targets bioactive signaling lipids for treating a wide range of human disease. Lpath’s ImmuneY2™ drug-discovery engine has the unique ability to generate therapeutic antibodies that bind to and inhibit bioactive lipids that contribute to disease. The company is currently advancing three drug candidates, two of which -- ASONEP™ for cancer and iSONEP™ for wet AMD -- have completed Phase 1 clinical trials. For more information, go to www.Lpath.com.
Company Contact:
Scott R. Pancoast
President & CEO
Lpath, Inc.
858-678-0800 x104
Email Contact
Investor Relations:
Scott Liolios or Ron Both
Liolios Group, Inc.
949-547-3860
Email Contact
